TapImmune Inc (MRKR) Given Consensus Rating of “Hold” by Analysts
TapImmune Inc (NASDAQ:MRKR) has received an average broker rating score of 2.50 (Hold) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and one has assigned a buy rating to the company. TapImmune’s rating score has declined by 25% from 90 days ago as a result of various analysts’ ratings changes.
Analysts have set a 1-year consensus price objective of $7.50 for the company and are predicting that the company will post ($0.22) earnings per share for the current quarter, according to Zacks. Zacks has also assigned TapImmune an industry rank of 103 out of 257 based on the ratings given to related companies.
Separately, Piper Jaffray Companies started coverage on TapImmune in a research note on Monday, October 22nd. They issued a “neutral” rating for the company.
TapImmune (NASDAQ:MRKR) last released its quarterly earnings data on Tuesday, November 13th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.12. Equities research analysts anticipate that TapImmune will post -1.26 earnings per share for the current year.
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Recommended Story: Why investors pay attention to retained earnings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.